BioCardia to Participate in Upcoming Investor Conferences

Rhea-AI Summary

BioCardia announced its participation in two virtual investor conferences. The Q3 Investor Summit Virtual Conference will take place from August 17-18, 2021, with a corporate presentation on August 17 at 2pm ET. The SNN Network Virtual Event Conference, scheduled for August 17-19, 2021, will feature a corporate presentation on August 19 at 3pm ET. Attendees can sign up for one-on-one meetings with company representatives via the conference websites. BioCardia focuses on developing therapeutics for cardiovascular and pulmonary diseases.

SAN CARLOS, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- BioCardia^®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that the Company’s management team will participate in the following upcoming investor conferences:

• Q3 Investor Summit Virtual Conference from August 17-18, 2021 https://investorsummitgroup.com/conferences/
  • BioCardia Corporate Presentation scheduled for 08/17 at 2pm Eastern Time (11am Pacific time)
  • 1-1 meetings available with Company Representatives for those interested – please sign up through conference website.
• SNN Network Virtual Event Conference from August 17-19, 2021 https://conference.snn.network/
  • BioCardia Corporate Presentation scheduled for 08/19 at 3pm Eastern Time (12pm Pacific time)
  • 1-1 meetings available with Company Representatives for those interested – please sign up through conference website.

About BioCardia^®

BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMP^TM autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogenic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.  These platforms underly four product candidates, each with the potential to meaningfully benefit millions of patients. Three of these investigational therapies are enabled by the Company’s proprietary biotherapeutic delivery platforms, which the Company also selectively licenses to other biotherapeutic development firms.

INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@BioCardia.com
(650) 226-0120

MEDIA CONTACT:
Anne Laluc, Marketing
Email: alaluc@biocardia.com
Phone: 650-226-0120

FAQ

What are the dates for BioCardia's upcoming investor conferences?

BioCardia will participate in the Q3 Investor Summit Virtual Conference from August 17-18, 2021, and the SNN Network Virtual Event Conference from August 17-19, 2021.

When is BioCardia's corporate presentation at the Q3 Investor Summit?

BioCardia's corporate presentation at the Q3 Investor Summit is scheduled for August 17, 2021, at 2pm Eastern Time.

When will BioCardia present at the SNN Network Virtual Event Conference?

BioCardia's corporate presentation at the SNN Network Virtual Event Conference is set for August 19, 2021, at 3pm Eastern Time.

How can investors schedule one-on-one meetings with BioCardia representatives?

Investors can sign up for one-on-one meetings with BioCardia representatives through the respective conference websites.

What is BioCardia's focus in biotherapeutics?

BioCardia focuses on developing cellular and cell-derived therapeutics for treating cardiovascular and pulmonary diseases.